The presence of a TGM2‐inhibiting antibody28 reduced the expression of fibrotic markers in scleroderma cells that were observed with a pan‐TGF‐β neutralizing antibody and an ALK5 inhibitor. The gene discussed is TGFBR1; the disease is scleroderma.